Inovio Pharmaceuticals/INO

$9.02

10.53%
-
1D1W1MYTD1YMAX

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. The Company’s lead candidates are focused on diseases associated with HPV. Its DNA medicines pipeline includes INO-3107 for HPV-related Recurrent Respiratory Papillomatosis (RRP), VGX-3100 for the treatment of HPV-related Cervical HSIL, INO-5401 for the treatment of Glioblastoma Multiforme (GBM), INO-5151 (INO-5150 + INO-9012) for the treatment of Prostate Cancer, INO-4800 for COVID-19, INO-4201 for Ebola Virus Disease, INO-4700 for Middle East Respiratory Syndrome (MERS) and INO-4500 for Lassa Fever. Its DNA medicine platform consists of DNA plasmids and its investigational smart device, CELLECTRA, which is used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of three models.

Ticker

INO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jacqueline Shea

Employees

184

Headquarters

San diego, United States

INO Metrics

BasicAdvanced
$185.63M
Market cap
-
P/E ratio
-$7.62
EPS
1.01
Beta
-
Dividend rate

What the Analysts think about INO

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
108.76% upside
High $40.00
Low $4.50
$9.02
Current price
$18.83
Average price target

INO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-11,300% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$300K
50%
Net income
$-33.9M
-4.51%
Profit margin
-11,300%
-36.34%

INO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.63%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$2.52
-$1.92
-$1.56
-$1.56
-
Expected
-$2.02
-$1.74
-$1.74
-$1.52
-$1.27
Surprise
25%
10.34%
-10.34%
2.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Inovio Pharmaceuticals stock

Buy or sell Inovio Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing